Xregen Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2022

Location

Hangzhou Zhejiang China

Primary Industry

Biotechnology

About

Established in 2022 and based in Hangzhou, China, Xregen is a developer of height-enhancing technology for children, focusing on human genetic diagnosis and therapeutic technology development. As of 2023, it has more than 20 employees. Their product, Angaosu, has been launched in November 2022. The chief scientist, Academician Wen, specializes in regenerating the organism by adjusting the cellular microenvironment. The company focuses on developing height enhancement solutions for children, and also includes human genetic diagnosis and treatment technology development, bio-based material polymerization technology development, medical research, and trial development. Currently, IKids-Growth, the company's exclusive IGF-1 (growth promoting factor) height enhancement solution, has passed real-world studies.

Current Investors

K2VC, Oufang Angel, Wangdao Venture Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Healthcare Specialists

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

Employee Data

Want to see the Employee Count?

Request a demo for full access to this profile.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.